NICE has issued final draft guidance recommending Tryngolza (olezarsen) for adults in England and Wales with genetically confirmed familial chylomicronaemia syndrome, but only when response to diet ...

Boehringer Ingelheim has reported new phase 3 data showing its dual glucagon/GLP‑1 agonist survodutide achieved weight loss of up to 13.1% in adults with obesity and type 2 diabetes. The SYNCHRONIZE‑2 ...

Kither Biotech has started dosing patients in its phase 1b / 2a clinical study of KIT2014 in adults with moderate to severe ...

Quotient Sciences and Acesion Pharma have formed a new collaboration to apply AI‑enhanced formulation development within Quotient’s Translational Pharmaceutics platform. The partnership will support ...

Teva has received US FDA approval for DEGEVMA (denosumab‑adet), a biosimilar to Xgeva, marking a further step in its Pivot to Growth strategy. The product is authorised across all Xgeva indications, ...

Neuraxpharm and Minoryx have announced that the European Commission has granted marketing authorisation under exceptional ...

For years, the functional service provider (FSP) model has given sponsors a practical way to extend internal teams and access specialist capabilities. What began primarily as a tactical resourcing ...

Maternity care is one of the most fundamental components of any healthcare system. It shapes not only the health of mothers and babies, but the long-term well-being of families and communities. Yet ...

It’s been over a year since the announcement of the Single National Formulary (SNF). No question – this is a really big one for pharma, and at my new company, Life Science Access Academy, we’re ...